Zimmer revises its $13 billion bid for crosstown rival Biomet in a further effort to mollify European anti-trust regulators, saying it thinks the deal is still on track to close during the 1st quarter.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1CdH2s7
Cap comentari:
Publica un comentari a l'entrada